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The purposes of acute toxicity testing are to obtain information on the biologic activity of a
chemical and gain insight into its mechanism of action. The information on acute systemic toxicity
generated by the test is used in hazard identification and risk management in the context of
production, handling, and use of chemicals. The LD50 value, defined as the statistically derived
dose that, when administered in an acute toxicity test, is expected to cause death in 50% of the
treated animals in a given period, is currently the basis for toxicologic classification of chemicals.
For a classical LD50 study, laboratory mice and rats are the species typically selected. Often both
sexes must be used for regulatory purposes. When oral administration is combined with
parenteral, information on the bioavailability of the tested compound is obtained. The result of the
extensive discussions on the significance of the LD50 value and the concomitant development of
alternative procedures is that authorities today do not usually demand classical LD50 tests
involving a large number of animals. The limit test, the fixed-dose procedure, the toxic class
method, and the up-and-down methods all represent simplified alternatives using only a few
animals. Efforts have also been made to develop in vitro systems; e.g., it has been suggested
that acute systemic toxicity can be broken down into a number of biokinetic, cellular, and
molecular elements, each of which can be identified and quantified in appropriate models. The
various elements may then be used in different combinations to model large numbers of toxic
events to predict hazard and classify compounds. Environ Health Perspect 106(Suppl 2):
497-503 (1998). http://ehpnetl.niehs.nih.gov/docs/1998/Suppl-2/497-503walum/abstract.html
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Introduction
This paper gives a short review ofmethods
for acute toxicity testing with the emphasis
on the median lethal dose (LD50) test and
alternative procedures that fulfill the
requirement ofreducing, refining, or replac-
ing the use of animals in toxicity testing
(the 3Rprinciple). Furthermore, this review
mirrors the current discussion on the use-
fulness of different procedures for acute
toxicity testing and surveys the conclusions
ofvarious panels, commissions, and groups.
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Organisation for Economic Co-operation and
Development; PLS, partial least square modeling with
latent variables.
Acute toxicity is usually defined as the
adverse change(s) occurring immediately or
a short time following a single or short
period of exposure to a substance or sub-
stances or as adverse effects occurring
within a short time of administration of a
single dose ofa substance or multiple doses
given within 24 hr. An adverse effect is
"any effect that results in functional
impairment and/or biochemical lesions
that may affect the performance of the
whole organism or that reduce the organ's
ability to respond to an additional chal-
lenge" (1). Consequently, a chemical that
enters the organism via the oral route dur-
ing a restricted time and produces any
adverse effect with little delay is orally and
acutely toxic. However, the term acute oral
toxicity is most often used in connection to
lethality and LD50 determinations.
Studies of acute systemic toxicity
attempt to determine the dose-dependent
adverse effect that may occur and various
appropriate data may be collected when
determining the comprehensive acute
toxicity profile of a substance. This may
include the incidence of lethality. It has
been claimed thatwhen properlyperformed
and closely observed, an acute toxicity test
can give more information about the bio-
logic properties of a chemical compound
than any other single test, and even if the
incidence oflethality were never computed
as a consequence ofsuch a test, one would
only have lost a small proportion of the
available information (2). If the dose-
dependent lethality incidence is deter-
mined in a precise manner, it is usually
expressed as an LD50. This is defined as the
statistically derived dose that, when admin-
istered in an acute toxicity test, is expected
to cause death in 50% of the treated ani-
mals in a given period (3). For a classical
LD50 study, laboratory mice and rats are
species typically selected. Often the use of
both sexes and a route of exposure antic-
ipated to be the most probable route of
exposure for humans are necessary for reg-
ulatory purposes. When oral adminis-
tration is combined with parenteral,
information on the bioavailability of the
tested compound is obtained.
The purposes of acute toxicity testing
are to obtain information on the biologic
activity ofa chemical and gain insight into
its mechanism ofaction. Long-term studies
usually start with a dose-finding exercise
under acute conditions. Furthermore, the
information on acute systemic toxicity gen-
erated by the test is used in hazard identifi-
cation and risk management in the context
ofproduction, handling, and use ofchemi-
cals. The LD50 value (precise or approxi-
mate) is currently the basis for toxicologic
classification of chemicals and is thus
required by government authorities in dif-
ferent situations. The dosed animals are
closely observed during the first 24 hr and
then day by day for as long as 2 weeks and
changes in appearance and behavior are
noted. A large number ofclinical signs can
be used to characterize acute systemic toxi-
city and describe its progression (1). There
is some question concerning the use of
extensive pathologic assessment as part of
an acute study. However, gross necropsies
are the minimum requested by most gov-
ernmental regulatory bodies, as are weight
determinations prior to dosing and after 1
and 2 weeks. Determination of a precise
LD50 value within an acute toxicity study
is motivated mainly by the authorities' dif-
ferent requirements for classification of
chemicals. In the past the LD50 has been
used for industrial chemicals as the basis
for the various toxicity classification sys-
tems that are or have been in operation
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throughout the world (3). At present the
following chemical labeling and classifica-
tion of acute systemic toxicity based on
oral LD50 values are recommended by the
Organisation for Economic Co-operation
and Development (OECD): very toxic, <5
mg/kg body weight; toxic, >5<50 mg/kg;
harmful, >50<500 mg/kg; and no label,
>500<2000 mg/kg.
The absolute LD50 value for a com-
pound varies among different laboratories,
and these variations have been attributed to
differences in e.g., protocol details, animal
strains, caging, and test-chemical source.
LD50 and alternative methods for testing of
acute toxicity have been discussed exten-
sively in different international forums
during the last two decades (1,3-7). In par-
ticular, thenecessity to determine ahigh sta-
tistical accuracy in the LD50 value has been
questioned. Oliver (3) has summarized the
twomajorpoints ofcriticism clearly.
First, he states that the median lethal
dose is not an absolute value but is an
inherendy variable biologic parameter that
cannot be compared to constants such as
molecular weight or melting point. This
means that an LD50 cannot be described in
terms of accuracy, only of precision. In
addition, the precision is relevant only for
the experiment from which the LD50 was
derived and does not increase the probabil-
ity that in subsequent experiments the
LD50 will be identical or even similar (3).
Oliver's second point is that the value
refers only to mortality and is illustrative
of no other clinical expression of toxicity.
The representation ofa compound's acute
systemic toxicity as its LD50 is considered
a descriptive limitation that outweighs the
otherwise obvious attraction ofconverting
a sometimes complex picture into a simple
numerical index that can be subsequently
utilized by those who have a limited
understanding oftoxicology (3).
The result of the extensive discussions
on the significance of the LD50 value and
the concomitant development of alterna-
tive procedures is that authorities today do
not usually demand classical LD50 tests
involving a large number of animals, i.e.,
10 animals per group, 10 doses, and both
sexes-a total of200 animals. On the con-
trary, OECD guidelines 401 (8), 420 (9),
and 423 (10) describe well established, val-
idated alternative methods that reduce ani-
mal suffering and/or use much fewer
animals than the classical method (4).
Using one of these tests, the number of
animals required for determining an LD50
value can be reduced by one order of
magnitude. However, these methods can
be considered adaptations to the shortcom-
ings of LD50 determinations rather than
attempts to improve the scientific value of
quantitative acute systemic toxicity studies.
Efforts have also been made to combine a
more scientific view on acute toxicity test-
ing with the development of alternative
methods. One example is the idea that
acute systemic toxicity can be broken down
into a number of biokinetic, cellular, and
molecular elements, each ofwhich can be
identified and quantified in appropriate
model systems. The various elements can
then be used in different combinations to
model large numbers of toxic events.
Whereas the standard animal model is
fixed, the integrated in vitro system can be
optimized for acertain dass ofcompounds,
a specific mechanism of action, or a par-
ticular target organism. The programs of
the Multicenter Evaluation of In Vitro
Cytotoxicity (MEIC) (11-13) and the
integrated toxicity testing scheme of the
European Research Group for Alternatives
in Toxicity Testing/Swedish National
Board for LaboratoryAnimals (14) address
these theories, and the use ofin vitro meth-
ods for the classification and labeling of
chemicals has been proposed by Seibert et
al. (15) and further reviewed by Seibert et
al. (7). In summary, the following scheme
is proposed (Figure 1): as a first step, a test
for general cytotoxicity activity would be
conducted. The results would be converted
to an equivalent effective body dose by
means of a prediction model based on
physicochemical data and basic assump-
tions about toxicokinetic parameters in
vivo and in vitro. If the results were posi-
tive, that is, ifthey indicated that the com-
pound should be classified as very toxic, no
further testing would be needed. If the
results were negative, Stage 2 testingwould
be performed. Again, if the results were
positive (that is, dassification in the highest
toxicity dass was indicated), testing would
be stopped at this stage. If not, Stage 3
testing would be performed. Finally, the
chemical would be classified as very toxic,
toxic, harmful, or no label, according to
the lowest median effective concentration
value determined at anyofthe three testing
levels. If the results indicated that the
chemical should be assigned to the lowest
toxicity class, a limited in vivo study might
be needed.
LimitTest
Thelimit test, described in OECD guideline
401 (8), is a restricted version of an acute
toxicity test and is used after a range-
finding study or a literature search has
made it likely that the chemical is oflow
toxicity. Several measures have been taken
to reduce the number ofanimals needed for
Classification
(verytoxic)
Classification
(verytoxic)
Classification
Figure 1. Athree-stage tiered scheme for in vitrotesting for acute systemic toxicity and forthe classification and
labeling ofchemicals [adaptedfrom Seibert etal. (7)1.
Environmental Health Perspectives * Vol 106, Supplement 2 * April 1998 498ACUTE ORAL TOXICITY
a complete study. The limit test ideally
involves the use ofthree groups (three dose
levels; the highest dose limit is set to 2 g/kg
and is the initial starting dose) of five ani-
mals ofa single sex, with assessment oftoxi-
city in the second sex in aseparate study. In
this second study five animals are used at a
single dose level to establish the absence of
anysignificant sexdifference in toxicity.
Fixed-DoseProcedure
The fixed-dose procedure was first proposed
by the British Toxicology Society in 1984
(16). After an international validation
study involving 20 reference chemicals
tested in 31 laboratories from 11 different
countries (17), the procedure was incorpo-
rated into the OECD guidelines (guideline
420) in 1992 (9). The results ofthe valida-
tion study showed a remarkable consistency
between laboratories and it was concluded
that the data generated could be used both
for risk assessment and ranking chemicals
for classification. Further evaluation of the
method has proven its usefulness (18-21).
The test substance is given at one ofthe
four fixed-dose levels (5, 50, 500, and
2000 mg/kg) to five male and five female
rats. The objective is to identify a dose that
produces clear signs oftoxicity but no mor-
tality (22). Depending on the results ofthe
first test, either no further testing is needed
or a higher or lower dose is tested: Ifmor-
tality occurs, retesting at a lower dose level
is necessary (except ifthe original dose cho-
sen is 5 mg/kg). If no signs of toxicity
occur at the initial dose, it is necessary to
retest at a higher dose level. The results are
thus interpreted in relation to animal sur-
vival and evident toxicity (5) and it
becomes possible to assign the chemical to
one ofthe OECD classification categories.
ToxicClassMethod
The toxic dass method has been validated
both nationally (23) and internationally
(24). The latter study included 20 test
substances and nine laboratories in five
countries. The method is described in
OECD guideline 423 (10) and is based on
the assessment of lethality. In principle
three animals are dosed with one of three
fixed levels corresponding to the oral LD50
classification limits. The purpose of the
procedure is to identify the lowest dose
level that causes two or three animals to
die. Three animals of one sex are dosed at
the middle level. If two or three animals
die, retesting is done at the lower level.
When fewer than two die, the test is
repeated at the same level, but with the
other sex. If two or three animals die in
this step, the test is repeated at the lower
level, and iffewer than two die, the test is
repeated at the higher level. Several studies
have evaluated the method and found it a
valuable alternative test for classification of
chemicals (20,25).
Up-and-DownMethod
In this type ofprocedure asingle animal (or
sometimes two to four animals) is exposed
with subsequent doses adjusted up or down
by a constant factor depending on the out-
come ofthe previous dose (26). If an ani-
mal dies during the initial step of the test,
another animal is given a dose reduced by a
factor of, e.g., 1.3. Ifthis exposure does not
result in toxicity, the dose is elevated by an
equivalent constant factor until five animals
have been dosed or the limit dose is
reached. Although time consuming, the up-
and-down procedure can give good results
with the use ofas few as six to nine animals
(18,21). Proposals are being circulated for
acceptance of the up-and-down method
into OECD guidelines (27).
Predictive Power ofAnimal
Testsfor Human Toxicity
The problem of extrapolation of animal
data to humans is well recognized (28).
According to Garattini (29) there are three
main points to address: a) different animal
species dispose of chemicals in different
ways; therefore, the concept ofdoses (e.g.,
milligram/kilogram body weight) should be
gradually replaced by the use ofconcentra-
tions (mol/blood or tissue volume); b) bio-
transformation of chemicals may lead to
metabolites with biologic activity; hence we
need to know more preciselywhat chemical
species are responsible forwhich toxicologic
effect; c) equal concentrations ofchemicals
do not mean equal effects across animal
species because the sensitivity of organs,
cells, enzymes, or receptors maybe different
in different species. These three aspects
must be considered in relation to other fac-
tors capable of modulating toxic effects,
e.g., strain, sex, age, concomitant pathol-
ogy, hereditary defects, and previous or
concomitant exposure to otherchemicals.
The MEIC program was instigated by
the Scandinavian Society of Cell Toxi-
cology to investigate the relevance of in
vitro cytotoxicity for the prediction of
human acute and sublethal toxicity, suba-
cute toxicity, organ-specific toxicity, and
local irritance. The first 50 reference chem-
icals (Table 1) were chosen by the Swedish
Poison Information Centre because they
have known lethal doses and blood
concentrations in humans (clinical and/or
autopsy data) plus good animal (rat and
mouse) LD50 data. One ofthe first priori-
ties of the MEIC program was to use this
information to investigate the predictivity
of rat and mouse lethal doses for human
lethal dosage to be used as reference for the
later in vitro prediction ofhuman toxicity
(11). A preliminary calculation involving
30 MEIC chemicals showed a good corre-
lation between animal and human data and
indicated that human acute lethal doses
were better predicted by the mouse than
the rat data (13). The final MEIC eval-
uation, performed on all 50 chemicals,
confirmed these results: rat LD50 values
predicted human acute doses less well
(r2=0.61; Figure 2A), whereas mouse
LD50 values correlated somewhat better
(r2=0.65; Figure 2B) (30,31).
The relationship between body weight,
body surface area, specific surface area,
and/or basal metabolic rate and oral LD50
has been investigated in several studies. It is
evident that the predictive power ofanimal
LD50 determinations for human toxicity
can be improved if these parameters are
accounted for in the extrapolation model
[reviewed by Rhodes et al. (1)].
Cytotoxicity Determinations
In many investigations attempts have been
made to find a correlation between simple
cytotoxicity determinations in vitro and
animal LD50 for manychemicals.
Despite the fact that such a relation-
ship seems unlikely, many reports claim to
have established a good correlation (e.g.,
32-35). Furthermore, these data cannot be
dismissed as merely the result ofgood (or
bad) luck, poor statistical methods, or the
use of too few reference chemicals: a firm
relationship between cytotoxicity in vitro
and systemic toxicity in vivo does exist. A
hypothesis has been presented (12) that
could explain the existence of such a con-
nection. The concept of basal cytotoxicity
states that the mechanisms of action of
most toxic chemicals are related to bio-
chemical processes expressed in all cells.
Consequently, toxic concentrations may be
determined in vitroaswell as in vivo.
It is often claimed that because there
are so many different possible targets for a
toxic compound in the whole organism, it
is difficult to decidewhich model system to
choose as an in vitro test. According to the
notion of basal cytotoxicity, most toxic
chemicals exert their ultimate action by
interference with basic cellular functions.
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Tale1. Oral LDw dosesfor ratand mouseand mean oral lethaldoseforhumans.
Average dose
Chemical LDWrat,pmol/kg LD5omouse, pmol/kg human,pmol/kg
Paracetamol 15899 2235 1795.16
Ferroussulfate 2100 4477 3581.02
Amitriptline 505 133.80
Ethyleneglycol 75,684 88,567 25,304.81
Ethanol 153,145 74,837 102,262.16
1,1,1 -Trichlorethane 71,964 44,978 53,544.86
Sodium chloride 51,370 68,493 39138.94
Malathion 878 575 2248.36
Xylene 40,490 19,953 8474.58
Potassiumganide 77 131 43.89
Theophylline 1354 1304 872.05
Propamolol HCL 1575 1082 241.71
Parnaqa 537 644 214.71
Cupric.sulfate 12
ThioidazineHCL 2445 946 168.4HC
Warfarin 5 10 347.42
Chloroform 7 302 8375.21
lsoniazid 9117 970 1250.39
Bariumnitrate 1358 1016 142.09
Pentachloro 101 105 107.25
Chlor ulne phosphat 1208 969 163.38
Quinidinesulfate 10 676 187.42
Chloramphenicol 7735 4641 884.02
Amphetaminesulfate 149 65 54.27
Altro inesulfate 864 674 2.47
These functions are fundamental to all cells,
regardless ofwhether they are in in vivo or
in vitro situations. Ifthe assumption is cor-
rect, chemically unrelated compounds with
a wide range of toxic mechanisms can be
tested for their acute toxicities in relatively
simple cell culture systems. Support for this
thought has been obtained through the
interlaboratory validation programs of the
Foundation for the Replacement of
Animals in Medical Experiments and the
MEIC, which have shown that cytotoxicity
ranking is largely independent of the cell
type and the end point used in the particu-
lar test. The idea of basal cytotoxicity also
explains why there is not a perfect match
between in vitro and in vivo data: Because
the biochemical targets for toxicity are not
expressed equally in all cells, the toxic con-
centration ofcompounds with a very spe-
cific action will differ between organs as
well as between species. An important func-
tion ofcells in vivo is theirability to metab-
olize chemicals to more- or less-toxic
compounds. This function is usually
expressed to a small extent in cultured cells,
which results in limited activation ordeacti-
vation of test chemicals or in the in vitro
accumulation of intermediates that do not
occur in vivo. This fact, together with the
lack ofother toxicokinetic functions in the
cell culture system, further adds to the
restrained in vivo-in vitrocorrelation.
In traditional toxicology the organism
tends to be regarded as the primary unit for
theexpression oftoxic effects. Consequently,
the onset and duration ofeffects, as well as
the effects themselves (e.g., changes in
behavior and alterations in blood flow, renal
functions, and metabolic parameters),
become signs ofimpaired homeostasis and
are inevitably bound to the intact organism.
In in vitro toxicology the cell is considered
the toxicologic unit. Whole-animal reactions
are thus transformed into perturbations of
cellular functions. Chemicals exert their
actions on different levels ofcellular organi-
zation. Basal cytotoxicity represents the most
fundamental and most common form ofcel-
lular toxicity. Chemicals can also interfere
with differentiated functions and thereby
cause organ-specific effects. Finally, at the
highest level of integration, intercellular
functions areimpaired.
The importance of toxicokinetic
considerations in the extrapolation of ani-
mal data to the human situation hasalready
been emphasized. In the simplest case, the
oral acute toxicity ofa chemical is tested on
one species, with the recording of symp-
toms; the determined lethal dose is a func-
tion of the absorption, distribution,
biotransformation, excretion, and critical
target organ concentration ofthe chemical.
The value ofthe prediction ofacute human
toxicity based on this information will
depend on the similarity between the test
species and humans in all the events
involved. The death of the animal because
ofone critical effect, which may or may not
be relevant to humans, will prevent an eval-
uation of the other important effects. The
modeling ofquantitative toxicity in vitro is
more scientific and less of a gamble. It
involves a multiple analysis of many para-
meters, which can be studied separately or
in combination-a procedure that can be
designed to fit the questions asked. Pre-
dictions are modeled on primary data and
can easily be connected directlywith mech-
anistic studies in the same in vitro systems.
Each piece of data can be evaluated in
terms ofits relevance for the corresponding
human event. This results in an ability to
control uncertainty of each element, and
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Figure 2. Linear regression analysis ofthe prediction of human acute toxicity by(A) rat and (8) mouseLD5 values
[adapted from Ekwall et al. (31)1. A)y=0.829x0.877; r2=0.607. B)y=0.902x0.551; r2=0.653.
thereby the whole model. Whereas the
animal model can only be improved in a
limited sense, i.e., by the adoption of more
sophisticated end point measurements and
the alterations ofsingle genes or the intro-
duction ofnewgenetic material, the in vitro
approach can be continuously developed
from primitive methods that give restricted
predictions to sophisticated, more reliable
models with a mechanistic basis.
Predictive Power
ofCytotoxicityTests
for Human Toxicity
As part of the MEIC program and as its
prime effort, approximately 30 laboratories
have tested the 50 MEIC reference chem-
icals (Table 1) in a total of 68 in vitro
cytotoxicity tests, resulting in median inhibi-
tory concentrations (IC50 values) for differ-
ent exposure and observation times, cell
types, and toxicity criteria (33). These results
have recendy been analyzed (31) according
to principles agreed on and published at the
start ofthe program (11). All 68 sets ofIC50
values were compared by multivariate partial
least squares (PLS) analysis to acute lethal
blood concentrations in humans. The
human data were obtained from both dini-
cal and forensic medicine handbooks. Values
for peak concentrations from median lethal
concentration (LC50) curves over time were
included. Furthermore, average values from
the most predictive tests have been prelimi-
narily compared to handbook lethal concen-
trations aswell as to peaks and 24- and 48-hr
values from the LC50 curves by linear regres-
sion analysis. The latter analysis also tested a
previous hypothesis (36) on aprobable extra
sensitivityofthe brain to basal cytotoxicity.
The following results were obtained
from this first preliminary analysis: the PLS
multivariate analysis indicated that most of
the 68 tests provided the same information
with agood total, induding all tests, predic-
tion ofhuman handbook lethal concentra-
tions (r2 =0.73), and peak concentrations
from LC50 curves (r2 =0.78). Tests with
human cells were the most predictive; aver-
age IC5o values for all ten 24-hr cytotoxicity
tests with human cell lines predicted
human handbook lethal concentrations rea-
sonably well (clinical, r2 =0.69; forensic,
r2= 0.70) and peaks from human LC50
curves similarly (r2 =0.74). When IC50 val-
ues for the 32 chemicals in the study,
known to pass the blood-brain barrier
freely, were compensated for brain sensitiv-
ity by a 10 x reduction, the average human
cell line cytotoxicity for all 50 chemicals
predicted peak values from LC50 curves
much better (r2 =0.84).
It may be concluded, therefore, that
cytotoxicity tests with human cell lines pre-
dict human lethal blood concentrations in
parity with mouse and rat LD50 predic-
tions ofhuman acute doses for the 50 ref-
erence chemicals. Moreover, the human
cell line prediction may be improved by
simple toxicokinetic knowledge, i.e., data
on blood-brain barrier penetration, to pre-
dict human toxicity even better than the
standard animal test.
Conclusions
With threewell established alternative meth-
ods to the classical LD50 test it should be
possible to abandon the latter in favor ofthe
more humane fixed-dose procedure, acute
toxicity class method, and up-and-down
method (27). In vitro methods do not yet
represent a realistic alternative to in vivo
methods for regulatory acute oral toxicity
determinations. The problem oftranslating
in vitro toxic concentrations into in vivo
doses requires further research and develop-
ment (7,12,15,28,29,31). However, in cases
in which acute toxicity testing is performed
for reasons other than those requested by
government or medical authorities, e.g.,
screening as part of chemical and drug
development, it may be possible to replace
in vivo studies with cytotoxicity measure-
ments because a good picture ofthe signifi-
cance of in vitroacute toxicitystudies for in
vivotoxicityis emerging.
The condusions and recommendations
of the Workshop on Acute Toxicity
Testing, sponsored by the European
Centre for the Validation ofAlternative
Methods (ECVAM) (7) are summarized
here because they outline the state of the
art. The recommendations are as follows:
* In vitro toxicity tests could be used in a
tiered testing scheme to reduce the num-
ber ofanimals used and to reduce animal
suffering. Such an approach is a natural
progression ofrecent attempts to refine
in vivo acute toxicity tests by the use of
sequential dosing methods, such as the
toxic dass and up-and-down procedures.
Furthermore, in vitro tests could be used
in conjunction with alternative in vivo
tests to optimize the choice ofthe initial
dose: in these in vivo tests, use of the
lowest number of animals possible
depends on the correct choice ofstarting
dose. This choice could be optimized by
conducting appropriate in vitro tests
prior to any animal tests that were then
considered to benecessary.
* Many studies have shown good correla-
tions between in vitro cytotoxicity data
obtainedwith undifferentiated cell lines
and LD50 data. However, acute sys-
temic toxicity can be caused by a vari-
ety of mechanisms. Therefore, basal
cytotoxicity tests are not sufficient to
cover all possible mechanisms of acute
toxicity and must be supplemented by
more sophisticated approaches.
* It is essential in any testing scheme that
a quantitative comparison be made of
the concentrations of test materials
that exert basal cytotoxicity as opposed
to selective cytotoxic or cell-specific
function effects.
* Ways must be found to take toxico-
kinetic parameters into account when
predictions of in vivo data are based on
in vitrodata.
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* The specific characteristics of the in
vitro system (e.g., protein content, cell
concentration, ratio of cell/membrane
volumes) in use in relation to the tested
chemical (e.g., pKa, lipophilicity,
volatility) must be considered.
* The detection of selective toxicity
requires a comparison of the toxicities
of the same chemical in different cell
types. A simple undifferentiated cell
line is not likely to give a toxicityvalue
representative for an effect mediated
by the interference of the chemical
with a very specific mechanism, nor is
a highly differentiated cell, which is
not representative of the cells of the
target organ.
* A three-stage tiered scheme for in vitro
testing ofacute systemic toxicity can be
used for the classification and labeling
ofchemicals (Figure 1).
The neurotoxicity of compounds that
penetrate the blood-brain barrier is an
important determinant of the final acute
toxicity. A number of in vitro models for
determining the ability of chemicals to
penetrate the blood-brain barrier are avail-
able (37). Furthermore, the conclusions and
recommendations from the ECVAM
Workshop on In Vitro Neurotoxicity
Testing (38) should be considered in the
development ofalternative methods for test-
ing ofacute toxicity. The main suggestions
in this report (38) are:
* To develop and evaluate alternative
experimental models and end points
relevant to human neurotoxicity.
* To foster collaboration among the
various European Union neuropharma-
cotoxicologic research initiatives to
develop new and specific biomarkers,
end points, and models for in vitro
neurotoxicologic studies.
* To devise and (pre)validate a three-
tiered in vitro model encompassing
basal cytotoxicologic, cell physiologic,
and neuronal cell-specific end points.
* To validate such a tiered testing scheme
on amulticenter basis under the auspices
ofECVAM.
* To use toxicokinetic data to modify in
vitro neurotoxic critical concentrations
in the final comparison with critical in
vivoconcentrations.
In summary, it is obvious that signifi-
cant progress is being made toward the
understanding ofthe different components
that constitute the complex events desig-
nated acute systemic toxicity. This under-
standing is required for the appropriate
modeling of the different toxicologic ele-
ments and therefore is a prerequisite for the
development ofalternative methods that do
not involve laboratory animals. It is also rec-
ognized that a single in vitro test cannot
replace the dassical LD50 test or its animal-
based alternatives. Tiered testing schemes
seem to represent the solution to the prob-
lem and such schemes should therefore be
developed, refined, optimized, and vali-
dated; when (or if) found to perform as nec-
essary, they should be implemented in
regulatorywork.
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